So I've been watching the weight loss drug space pretty closely, and there's something interesting happening with Novo Nordisk that's worth paying attention to right now. The stock got hammered recently - down nearly 15% after disappointing Q4 results and rough 2026 guidance. But here's the thing: their oral Wegovy launch is actually doing something pretty significant.

The best part? The news came from their biggest competitor. Eli Lilly's executives basically confirmed what we've been hoping to see - oral Wegovy isn't just stealing sales from the injectable version. According to their exec Kenneth Custer, most of these new prescriptions are coming from patients who never tried the injectable in the first place. That's market expansion, not cannibalization. Think about it: plenty of people avoid needles, and the storage requirements for injectables are a hassle, especially if you travel. An oral option changes the game for that whole segment.

Now here's where it gets interesting. Eli Lilly sees this as validation for their own upcoming oral GLP-1 candidate they're developing. But for Novo Nordisk itself? Even with oral Wegovy performing well, the company is still guiding for declining sales in 2026. Price pressure and competition are just too strong right now. So oral Wegovy helps, but it's not the silver bullet.

What could actually move the needle is their pipeline. They've got CagriSema awaiting approval - that's next-generation weight loss and diabetes therapy. Then there's amycretin in phase 3 trials, plus several other weight loss candidates in earlier stages. If any of these hit, the stock could finally get some real momentum.

The stock just hit a fresh 52-week low, which is interesting from a long-term perspective. Novo Nordisk's fundamentals are solid, the market they're in is massive, and they've got real innovation coming down the pipeline. For patient investors, this could be worth watching closely over the next 12-24 months as these new candidates progress.